Vivimed To Pay $1.9M To End Losartan Economic Loss Claims

By George Woolston · December 4, 2025, 3:17 PM EST

Vivimed has agreed to pay $1.9 million to settle economic loss claims from a class of consumers and insurers related to its losartan product in sprawling multidistrict litigation over contaminated blood...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login